FDA Approved: VYKAT XR — Original Application (Soleno Therapeutics, Inc.)

View source ↗

Summary

FDA approved VYKAT XR (diazoxide choline) through an Original Application for Soleno Therapeutics, indicated for congenital hyperinsulinism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hyperinsulinism

Drugs mentioned

• VYKAT XR (Diazoxide choline)

Snippet

ORIG AP for VYKAT XR (DIAZOXIDE CHOLINE)